	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	517	(glucagon-like adj peptide) or glp-1 or glp-2	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 13:58			0
2	BRS	L2	25206	liposome	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 13:59			0
3	BRS	L3	14	1 same 2	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 14:04			0
4	BRS	L4	6	1 same conjugate	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 14:04			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	517	(glucagon-like adj peptide) or glp-1 or glp-2	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 20:14			0
2	BRS	L2	182	1 same analog	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 20:15			0
3	BRS	L3	100	1 same fragment	USPAT; US-PGPUB; EPO; DERWENT	2002/05/27 20:15			0

Glucagons and Glucagon-Like Peptides

				USD
-15 °C	**Glucagon (1-29) (human, bovine, porcine)** H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH $C_{153}H_{225}N_{43}O_{49}S$ M_r:3482.80 [16941-32-5]	H-6790.0500 H-6790.1000	0.5 mg 1 mg	180.- 320.-
-15 °C	**(Des-His[1],Glu[9])-Glucagon (1-29) amide (human, bovine, porcine)** H-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Glu-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-NH_2 $C_{148}H_{221}N_{41}O_{47}S$ M_r:3358.70 [110084-95-2] Glucagon antagonist. *Lit. C.G.Unson et al., Peptides* ***10****, 1171 (1989)*	H-2754.0500 H-2754.1000	0.5 mg 1 mg	135.- 200.-
-15 °C	**Glucagon (1-37) (porcine)** H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-Lys-Arg-Asn-Lys-Asn-Asn-Ile-Ala-OH (Oxyntomodulin (porcine)) *Lit. D.Bataille et al., Peptides* ***2 (suppl. 2)****, 41 (1981)/ D.Bataille et al., Ann. N.Y. Acad. Sci.* ***527****, 168 (1988)*	H-6880.0500 H-6880.1000	0.5 mg 1 mg	430.- 785.-
-15 °C	**Glucagon (19-29) (human, bovine, porcine)** H-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH $C_{61}H_{89}N_{15}O_{18}S$ M_r:1352.53 [64790-15-4] This glucagon fragment inhibited both the Ca^{2+} activated and Mg^{2+} dependent ATPase activity and Ca^{2+} transport in liver plasma membranes with an efficiency 1000-fold higher than that of glucagon. It is likely to be the active peptide involved in the inhibition of the liver Ca^{2+} pump. *Lit. A.Mallat et al., Nature* ***325****, 620 (1987)*	H-2758.0001 H-2758.0005	1 mg 5 mg	35.- 145.-
-15 °C	**Glucagon-Like Peptide 1 amide (human)** H-His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH_2 (GLP-1 amide (human); Preproglucagon (72-107) amide (human)) $C_{184}H_{273}N_{51}O_{57}$ M_r:4111.50 [99658-04-5] *Lit. D.J.Drucker et al., Proc. Natl. Acad. Sci. USA* ***84****, 3434 (1987)/ J.J.Holst et al., FEBS Lett.* ***211****, 169 (1987)*	H-6025.0500 H-6025.1000	0.5 mg 1 mg	215.- 395.-

				USD
-15 °C	**Glucagon-Like Peptide 1 (7-36) amide (human)** H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH_2 (GLP-1 (7-36) amide (human); Preproglucagon (78-107) amide (human)) $C_{149}H_{226}N_{40}O_{45}$ M_r:3297.68 [107444-51-9] This GLP-1 fragment is secreted from the lower small intestine and shows a strong insulinotropic effect. It is presently considered as the most important incretin hormone. Its action is mediated by receptors expressed by the endocrine pancreatic B-cells. *Lit. B.Kreymann et al., Lancet* ***1987 II****, 1300/ G.I.Bell et al., Nature* ***304****, 368 (1983)/ C.Orskov and J.H.Nielsen, FEBS Lett.* ***229****, 175 (1988)/ J.-P.Raufman et al., J. Biol. Chem.* ***267****, 21432 (1992) / P.A.Martin and A.Faulkner, Comp. Biochem. Biophys.* ***105A****, 705 (1993)/ H.C.Fehmann et al., Peptides* ***15****, 453 (1994)/ M.A.Nauck et al., Exp. Clin. Endocrinol. Diabetes* ***105****, 187 (1997)*	H-6795.0500 H-6795.1000	0.5 mg 1 mg	180.- 320.-
new -15 °C	**(Ser[8])-Glucagon-Like Peptide 1 (7-36) amide (human)** H-His-Ser-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH_2 ((Ser[8])-GLP-1 (7-36) amide (human); (Ser[79])-Preproglucagon (78-107) amide (human)) The replacement of alanine by serine significantly improved the plasma stability of GLP-1 (7-36) amide against DPP IV without impairing its insulinotropic activity. This may indicate that this modification could improve the potential of GLP-1 in the treatment of type-II diabetes. *Lit. U.Ritzel et al., J. Endocrinol.* ***159****, 93 (1998)*	H-4592.0500 H-4592.1000	0.5 mg 1 mg	180.- 320.-
new -15 °C	**Glucagon-Like Peptide 2 (human)** H-His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH (GLP-2 (human); Preproglucagon (126-159) (human)) $C_{171}H_{266}N_{48}O_{56}S$ M_r:3922.35 Like GLP-1, GLP-2 is secreted from enteroendocrine cells in a nutrient-dependent manner in both rodents and humans. Currently GLP-2 is used as a potential therapeutic agent for human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency. *Lit. D.J.Drucker, Trends Endocrinol. Metab.* ***10****, 153 (1999)/ D.J.Drucker et al., J. Parenter. Enteral Nutr.* ***23****, 598 (1999)*	H-4766.0001 H-4766.0500	1 mg 0.5 mg	255.- 145.-
-15 °C	**D-Gluconyl-Val-Leu-Gly-Lys-NHEt** $C_{27}H_{52}N_6O_{10}$ M_r:620.74 [121459-49-2] Inhibitor of the Plasmodium falciparum proteinase (Ki = 480 µM) and of the erythrocyte invasion by Plasmodium falciparum merozoites (IC_{50} = 900 µM). *Lit. R.Mayer et al., J. Med. Chem.* ***34****, 3029 (1991)*	H-8530.0001 H-8530.0005 H-8530.0025	1 mg 5 mg 25 mg	30.- 115.- 455.-
	Glucose-Dependent Insulinotropic Polypeptide (human) (See Gastric Inhibitory Polypeptides and Fragments Page 415)	H-5645.0500 H-5645.1000	0.5 mg 1 mg	215.- 395.-
-15 °C	**(H-Glu(Cys-βNA)-OH)$_2$ (Disulfide bond)** ((H-γ-Glu-Cys-βNA)$_2$) $C_{36}H_{40}N_6O_8S_2$ M_r:748.88	K-1650:0050 K-1650.0250	50 mg 250 mg	70.- 285.-